Bosch RJ - Search Results

1

Varied Patterns of Decay of Intact Human Immunodeficiency Virus Type 1 Proviruses Over 2 Decades of Antiretroviral Therapy.

Gandhi RT, Bosch RJ, Mar H, Laird GM, Halvas EK, Hovind L, Collier AC, Riddler SA, Martin A, Ritter K, McMahon DK, Eron JJ, Cyktor JC, Mellors JW; AIDS Clinical Trials Group A5321 Team. Gandhi RT, et al. Among authors: bosch rj. J Infect Dis. 2023 Jun 15;227(12):1376-1380. doi: 10.1093/infdis/jiad039. J Infect Dis. 2023. PMID: 36763044 Free PMC article.

2

Association of T cell proliferative responses and phenotype with virus control in chronic progressive HIV-1 disease.

Malhotra U, Bosch RJ, Chan E, Wang R, Fischl MA, Collier AC, McElrath MJ. Malhotra U, et al. Among authors: bosch rj. J Infect Dis. 2004 Feb 1;189(3):515-9. doi: 10.1086/381038. Epub 2004 Jan 16. J Infect Dis. 2004. PMID: 14745710 Clinical Trial.

3

Genetic correlates of efavirenz hypersusceptibility.

Shulman NS, Bosch RJ, Mellors JW, Albrecht MA, Katzenstein DA. Shulman NS, et al. Among authors: bosch rj. AIDS. 2004 Sep 3;18(13):1781-5. doi: 10.1097/00002030-200409030-00006. AIDS. 2004. PMID: 15316338

4

Effect of adjunct hydroxyurea on helper T cell immunity in HIV type 1-infected patients with virological suppression.

Malhotra U, Bosch RJ, Wang R, Collier A, McElrath MJ. Malhotra U, et al. Among authors: bosch rj. AIDS Res Hum Retroviruses. 2004 Aug;20(8):807-12. doi: 10.1089/0889222041725226. AIDS Res Hum Retroviruses. 2004. PMID: 15320983 Clinical Trial.

5

Depletion of latent HIV-1 infection in vivo: a proof-of-concept study.

Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, Landay AL, Coombs RW, Richman DD, Mellors JW, Coffin JM, Bosch RJ, Margolis DM. Lehrman G, et al. Among authors: bosch rj. Lancet. 2005 Aug 13-19;366(9485):549-55. doi: 10.1016/S0140-6736(05)67098-5. Lancet. 2005. PMID: 16099290 Free PMC article.

6

Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors.

Clark SA, Shulman NS, Bosch RJ, Mellors JW. Clark SA, et al. Among authors: bosch rj. AIDS. 2006 Apr 24;20(7):981-4. doi: 10.1097/01.aids.0000222069.14878.44. AIDS. 2006. PMID: 16603849

7

Pretreatment factors associated with 3-year (144-week) virologic and immunologic responses to potent antiretroviral therapy.

Bosch RJ, Bennett K, Collier AC, Zackin R, Benson CA. Bosch RJ, et al. J Acquir Immune Defic Syndr. 2007 Mar 1;44(3):268-77. doi: 10.1097/QAI.0b013e31802c7e20. J Acquir Immune Defic Syndr. 2007. PMID: 17146370 Clinical Trial.

8

The prevalence and incidence of neurocognitive impairment in the HAART era.

Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, McArthur JC, Collier AC, Evans SR, Ellis RJ. Robertson KR, et al. Among authors: bosch rj. AIDS. 2007 Sep 12;21(14):1915-21. doi: 10.1097/QAD.0b013e32828e4e27. AIDS. 2007. PMID: 17721099

9

Effect of hydroxyurea and dideoxyinosine on intracellular 3'-deoxyadenosine-5'-triphosphate concentrations in HIV-infected patients.

Bakshi RP, Hamzeh F, Frank I, Eron JJ Jr, Bosch RJ, Rosenkranz SL, Cramer YS, Ussery M, Flexner C. Bakshi RP, et al. Among authors: bosch rj. AIDS Res Hum Retroviruses. 2007 Nov;23(11):1360-5. doi: 10.1089/aid.2007.0078. AIDS Res Hum Retroviruses. 2007. PMID: 18184078 Clinical Trial.

10

Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.

Archin NM, Eron JJ, Palmer S, Hartmann-Duff A, Martinson JA, Wiegand A, Bandarenko N, Schmitz JL, Bosch RJ, Landay AL, Coffin JM, Margolis DM. Archin NM, et al. Among authors: bosch rj. AIDS. 2008 Jun 19;22(10):1131-5. doi: 10.1097/QAD.0b013e3282fd6df4. AIDS. 2008. PMID: 18525258 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

409 results

Search Page